BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 20841485)

  • 1. Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway.
    Huntoon CJ; Nye MD; Geng L; Peterson KL; Flatten KS; Haluska P; Kaufmann SH; Karnitz LM
    Cancer Res; 2010 Nov; 70(21):8642-50. PubMed ID: 20841485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 17-AAG suppresses growth and invasion of lung adenocarcinoma cells via regulation of the LATS1/YAP pathway.
    Ye XY; Luo QQ; Xu YH; Tang NW; Niu XM; Li ZM; Shen SP; Lu S; Chen ZW
    J Cell Mol Med; 2015 Mar; 19(3):651-63. PubMed ID: 25712415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sphingosylphosphorylcholine regulates the Hippo signaling pathway in a dual manner.
    Kemppainen K; Wentus N; Lassila T; Laiho A; Törnquist K
    Cell Signal; 2016 Dec; 28(12):1894-1903. PubMed ID: 27634386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
    Mana-Capelli S; McCollum D
    J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
    Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.
    Adler JJ; Johnson DE; Heller BL; Bringman LR; Ranahan WP; Conwell MD; Sun Y; Hudmon A; Wells CD
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17368-73. PubMed ID: 24101513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells.
    Cervantes-Gomez F; Nimmanapalli R; Gandhi V
    J Pharmacol Exp Ther; 2011 Nov; 339(2):545-54. PubMed ID: 21821695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evolutionarily conserved negative feedback mechanism in the Hippo pathway reflects functional difference between LATS1 and LATS2.
    Park GS; Oh H; Kim M; Kim T; Johnson RL; Irvine KD; Lim DS
    Oncotarget; 2016 Apr; 7(17):24063-75. PubMed ID: 27006470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
    Hao Y; Chun A; Cheung K; Rashidi B; Yang X
    J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function.
    Li Y; Zhang T; Schwartz SJ; Sun D
    Nutr Cancer; 2011; 63(7):1151-9. PubMed ID: 21875325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells.
    Karkoulis PK; Stravopodis DJ; Margaritis LH; Voutsinas GE
    BMC Cancer; 2010 Sep; 10():481. PubMed ID: 20828379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.
    Lang SA; Klein D; Moser C; Gaumann A; Glockzin G; Dahlke MH; Dietmaier W; Bolder U; Schlitt HJ; Geissler EK; Stoeltzing O
    Mol Cancer Ther; 2007 Mar; 6(3):1123-32. PubMed ID: 17363505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth.
    Lang SA; Moser C; Gaumann A; Klein D; Glockzin G; Popp FC; Dahlke MH; Piso P; Schlitt HJ; Geissler EK; Stoeltzing O
    Clin Cancer Res; 2007 Nov; 13(21):6459-68. PubMed ID: 17975158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calmodulin activates the Hippo signaling pathway by promoting LATS1 kinase-mediated inhibitory phosphorylation of the transcriptional coactivator YAP.
    Thines L; Gorisse L; Li Z; Sayedyahossein S; Sacks DB
    J Biol Chem; 2022 May; 298(5):101839. PubMed ID: 35307353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin modulates radiosensitivity by downregulating serine/threonine kinase 38 via Sp1 inhibition.
    Enomoto A; Fukasawa T; Takamatsu N; Ito M; Morita A; Hosoi Y; Miyagawa K
    Eur J Cancer; 2013 Nov; 49(16):3547-58. PubMed ID: 23886587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Holmes JL; Sharp SY; Hobbs S; Workman P
    Cancer Res; 2008 Feb; 68(4):1188-97. PubMed ID: 18281495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation.
    Krishnamoorthy GP; Guida T; Alfano L; Avilla E; Santoro M; Carlomagno F; Melillo RM
    J Biol Chem; 2013 Jun; 288(24):17481-94. PubMed ID: 23629654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Heat Shock Protein 90 suppresses TWIST1 Transcription.
    Chong KY; Kang M; Garofalo F; Ueno D; Liang H; Cady S; Madarikan O; Pitruzzello N; Tsai CH; Hartwich TMP; Shuch BM; Yang-Hartwich Y
    Mol Pharmacol; 2019 Aug; 96(2):168-179. PubMed ID: 31175180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
    Sauvageot CM; Weatherbee JL; Kesari S; Winters SE; Barnes J; Dellagatta J; Ramakrishna NR; Stiles CD; Kung AL; Kieran MW; Wen PY
    Neuro Oncol; 2009 Apr; 11(2):109-21. PubMed ID: 18682579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.